Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
07 Maggio 2024 - 2:30PM
Journey Medical Corporation (“Journey Medical” or the “Company”)
(Nasdaq: DERM), a commercial-stage pharmaceutical company that
focuses on the selling and marketing of FDA-approved prescription
pharmaceutical products for the treatment of dermatological
conditions, today announced the Company will release its first
quarter 2024 financial results after the U.S. financial markets
close on Monday, May 13, 2024. Journey Medical management will
conduct a conference call and audio webcast on Monday, May 13, 2024
at 4:30 p.m. ET.
To listen to the conference call, interested
parties within the U.S. should dial 1-866-777-2509 (domestic) or
1-412-317-5413 (international). All callers should dial in
approximately 10 minutes prior to the scheduled start time and ask
to join the Journey Medical conference call. Participants can
register for the conference by navigating to
https://dpregister.com/sreg/10188768/fc6df642e0. Please note that
registered participants will receive their dial-in number upon
registration.
A live audio webcast can be accessed on the News
and Events page of the Investors section of Journey Medical’s
website, www.journeymedicalcorp.com, and will remain available for
replay for approximately 30 days after the conference call.
About Journey Medical
CorporationJourney Medical Corporation (Nasdaq: DERM)
(“Journey Medical”) is a commercial-stage pharmaceutical company
that primarily focuses on the selling and marketing of FDA-approved
prescription pharmaceutical products for the treatment of
dermatological conditions through its efficient sales and marketing
model. The company currently markets seven branded and two generic
products that help treat and heal common skin conditions. The
Journey Medical team comprises industry experts with extensive
experience in developing and commercializing some of dermatology’s
most successful prescription brands. Journey Medical is located in
Scottsdale, Arizona and was founded by Fortress Biotech, Inc.
(Nasdaq: FBIO). Journey Medical’s common stock is registered under
the Securities Exchange Act of 1934, as amended, and it files
periodic reports with the U.S. Securities and Exchange Commission
(“SEC”). For additional information about Journey Medical, visit
www.journeymedicalcorp.com.
Company Contact:Jaclyn Jaffe
Journey Medical Corporation(781) 652-4500ir@jmcderm.com
Media Relations Contact:Tony
Plohoros6 Degrees(908)
591-2839tplohoros@6degreespr.com
Grafico Azioni Fortress Biotech (NASDAQ:FBIO)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Fortress Biotech (NASDAQ:FBIO)
Storico
Da Nov 2023 a Nov 2024